Fig. 2
From: Rolapitant treats lung cancer by targeting deubiquitinase OTUD3
Rolapitant inhibits lung cancer cell growth by targeting OTUD3. A A549, H1299, H1975, H460 and BEAS-2B cells were treated with the indicated concentrations (0–40 μM) of Rolapitant for 72 h. Cell viability analysis was determined by CCK-8 assays. IC50 was analyzed by nonlinear regression using GraphPad Prism software. B Electron microscopy photographs of A549 cells treated with the indicated concentrations (10–40 μM) of Rolapitant or DMSO for 24 h. Scale bar, 100 μm. C OD value (450 nm) was determined by CCK-8 assays. A549, H1299, H1975, H460, BEAS-2B and HPAEPIC cells treated with DMSO or the indicated concentrations (10, 15, 20 μM) of Rolapitant at the times indicated. Cisplatin (10 μM) treated cells were used as a positive control. D Clone formation analysis of A549, H1299, H1975, H460 and BEAS-2B cells treated with DMSO or the indicated concentrations (10, 15, 20 μM) of Rolapitant for 10–14 days. Scale bar: 1 cm. Bar graph showed the numbers of clone formation. E Cell viability analysis of A549, H1299 control and OTUD3 knocking down groups were determined by CCK-8 assays at the indicated concentration (0–30 μM) of Rolapitant for 72 h. All the results were presented as the mean ± SD from 3 independent experiments. (n = 3, *p < 0.05, **p < 0.01, ***p < 0.001, ns = no significance, vs. DMSO)